期刊文献+

妇科肿瘤后装逆向调强放射治疗的剂量学和疗效研究 被引量:2

Dosimetry and Efficacy Research on the Afterloading Brachytherapy Inverse Intensity-Modulated Radiotherapy of Gynecological Tumor
下载PDF
导出
摘要 目的:探讨后装逆向调强放射治疗在妇科肿瘤治疗中的应用价值,为临床治疗的技术选择提供依据。方法:选取20例Ⅰ~Ⅲ期宫颈癌患者,随机分为A、B两组,各10例。Ⅰb期2例,Ⅱa期4例,Ⅱb期12例,Ⅲa期2例。病理分型:鳞癌16例,腺癌4例。以上诊断均经过病理学证实。平均年龄55.67岁(32岁~65岁)。A组病例行后装逆向调强放射治疗,采用Inverse Planning Simulated Annealing(IPSA)技术进行剂量优化设计,B组病例行三维适形后装放射治疗。A、B组患者均采用3根施源器,进行腔内照射并同步箱式四野等中心外照射,剂量为46 Gy/23次。依据曼彻斯特剂量学系统,给予A点(宫口上2 cm,宫腔中轴线左右旁开2 cm处为A点位置)处方剂量6 Gy/次,照射次数5次,2次/周。对比分析A、B两组患者的靶区剂量分布,危及器官(直肠、膀胱)受量,放射性并发症及近期疗效。结果:A组患者的靶区剂量适形度和均匀性均好于B组患者。患者0.5年~1.0年的肿瘤局部和区域控制率:A组患者分别为96%(95%CI,85%~99%)和95%(95%CI,81%~99%)。B组患者局分别为93%(95%CI,85%~99%)和92%(95%CI,81%~99%)。危及器官(直肠、膀胱)受量:A组患者的直肠、膀胱最大受量比B组患者小约35%。A组患者的直肠、膀胱75%处方剂量受照体积V75约只为B组患者的二分之一。放射性并发症:RTOG 1级反应:A组患者为1例,B组患者为6例。RTOG 2级反应:A组患者为0例,B组患者为3例。RTOG 3级反应:A组患者为0例,B组患者为1例。近期疗效:在A、B组患者放疗期间及治疗结束后,几乎所有患者的肿瘤均有不同程度的缩小,有效率(CR+PR)均为92%以上。结论:后装逆向调强放射治疗技术具有近期疗效明显,靶区剂量适形度、均匀性好,危及器官受量低,放射性并发症少等优点,值得在妇科肿瘤治疗中广泛应用。 Objective: To investigate the application value of the Afterloading Brachytherapy Inverse Intensity-Modulated Ra- diotherapy of Gynecological Tumor. Methods: 20 patients with cervical cancer, were randomly divided into A, B two groups, 10 cases in each. Stage I b 2 cases, stage Ⅱa 4 cases, stage Ⅱb 12 cases, stage Ⅲa 2 cases. Pathological types: Squamous Cell carcinoma 16 cases, Adenocarcinoma 4 cases. The average age was 55.67 years (32 years- 65 years old). Group A patients re- ceived the Afterloading Brachytherapy Inverse Intensity-Modulated Radiotherapy. The dose optimization technology was the In- verse Planning Simulated Annealing (IPSA) .Group B patients received the Three-Dimensional Comformal Atlerloading Brachytherapy. Group A and B patients were treated with 3 applicator for intracavitary irradiation and synchronous box around 4 fields isocenter external irradiation, prescription dose 46 Gy/23F. According to the Manchester system ,the prescription dose of A points (2 cm above the cervix, 2 cm both in the left and right sides of the axis of uterine cavity ) was 30 Gy in 5 fi:actions, 2 times each week. Analysed groups A and B patients about the target volume dose distribution, organs at risk (rectum, bladder), short-term curative effect and radioactive complications. Results: The dose conformal and homogeneity index of the target vol- ume of group A were better than group B. The 0.5 year~ 1.0 year tumor local and regional control rate :group A patients were 96% (95% CI,85%-99%) and 95% (95% CI,81%-99%), group A patients were 93% (95% CI,85%-99%)and 92% (95% CI, 81%-99%).Organs at risk (rectum, bladder): the maximum dose ~f rectum and bladder of group A patients were about 35% less than group B, The 75% prescription dose irradiated volume of rectum and bladder of group A patients were about only 1/2 ofgroup B. Radioactive complications:RTOG grade 1 reaction : group A: lcase, group B: 6 cases. RTOG grade 2 reaction : group A: 0 ease, group B: 3cases. RTOG grade 3 reaction : group A: 0 case, group B: leases. Short-term efficacy : the tumors size of group A and B patients had both reduced during and after the radiotherapy, efficiency (CR+PR) was more than 92%. Conclu- sions: Afterloading Brachytherapy Inverse Intensity-Modulated Radiotherapy technique have obvious short-term efficacy, bet- ter dose conformal and homogeneity index of the target volume, lower dose of organs at risk, fewer radioactive complications. It's worthy of widely applicated in the gynecological cancer therapy.
出处 《中国医学物理学杂志》 CSCD 2013年第6期4487-4490,共4页 Chinese Journal of Medical Physics
关键词 妇科肿瘤 后装逆向调强放射治疗 剂量学 危及器官 放射性并发症 Gynecologic Oncology IPSA Dosimetry Organ at risk Radioactive complications
  • 相关文献

参考文献9

  • 1Jianheng Sun. Radiotherapy for gynecological cancer[J]. Chinese Journal of Practical Gynecology and Obstetrics,2006,8: 8-9.
  • 2Wei Wang,Yifu Wang. International Federation of gynecology and Obstetrics (FIGO) revised the clinical cervical and vulvar cancer staging criteria [J]. Chinese Journal of Practical Gynecology and Obstetrics, 1996,12(6)379-379.
  • 3Chavaudra J.Bridier A.Deftnition of volumes in external radiotherapy: ICRU Reports 50 and 62 [J].Cancer Radiother,2001,5 (5): 472-478.
  • 4D M KUSHNER, MD, P A FLEMING, MD, A W KENNEDY, MD, D A WILKINSON, PhD, E LEE, MSc and P A SAFFLE, RTT. High dose rate 192Ir afterloading brachytherapy for cancer of the vagina[J]. The British Journal of Radiology, 2003,76:719.725.
  • 5ETIENNE LESSARD, M.SC., I-CHOW HSU, M.D., AND JEAN POULIOT, PH.D. Inverse planning for interstitial gynecologic template rachytherapy: truly anatomy-based planning [J]. Int. J. Radiation Oncology Biol. Phys.,2002, 54 (4): 1243-1251.
  • 6Weibo Yin,Xianzhi Gu. Oncology Radiation [M]. The third edition. Beijing: Peking Union Medical College press, 2002.1108-1109.
  • 7Cetingoz R, Ataman OU , Tunce| N , et al. Optimization in high dose rate brachytherapy for uterovaginal applications [J]. Radiother Oncol , 2001 , 58 (1) : 31-61.
  • 8Pantelis E , Papagiannis P , Anagnostopoulos G, et al. Evaluation of a TG243 compliant analytical dosimetry model in clinical 192Ir HDR brachytherapy treatment planning and assessment of the significance of source position and catheter reconstruction uncertainties [J]. Phys Med Biol , 2004 , 49 (1) : 55-67.
  • 9Garipagaoglu M , Tuncel N , Koseoglu FG, et al. Geometric and dosimetric variations of ICRU bladder and rectum reference points in vaginal cuff brachytherapy using ovoids [J]. Int J Radiat Oncol Biol Phys , 2004 ,58 (5) :1607-1615.

同被引文献14

  • 1Viswanathan AN, Thomadsen B. American brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles [J]. Brachytherapy, 2012, 11(1): 33-46.
  • 2Levitchi M, Claire CB, Quetin P, et al. Impact of dosimetric and clinical parameters on clinical side effects in cervix cancer patients treated with 3D pulse-dose-rate intracavitary brachytherapy[J]. Radiother Oncol, 2012, 103(3): 314-321.
  • 3Dimopoulos JC, Petrow P, Tanderup K, et al. Recommendations from gynaecological (GYN) GEC-ESTRO working group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy[J]. Radiother Oncol, 2012, 103(1): 113-122.
  • 4Uniyal SC, Sharma SD, Naithani UC. Dosimetric verification of a high dose rate brachytherapy treatment planning system in homogeneous and heterogeneous media[J]. Phys Med, 2013, 29(2): 171-177.
  • 5Viswanathan AN, Beriwal S, Santos JFDL, et al. American brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy[J]. Brachytherapy, 2012, 11(1): 47-52.
  • 6Miglierini P, Malhaire JP, Goasduff G, et al. Cervix cancer brachytherapy: high dose rate[J]. Cancer Radiother, 2014, 18(5-6): 452-457.
  • 7Mohamed S, Nielsen SK, Fokdal LU, et al. Feasibility of applyinga single treatment plan for both fractions in PDR image guided brachytherapy in cervix cancer[J]. Radiother Oncol, 2013, 107(1): 32-38.
  • 8Lang S, Nesvacil N, Kirisits C, et al. Uncertainty analysis for 3D image-based cervix cancer brachytherapy by repetitive MR imaging: ssessment of DVH-variations between two HDR fractions within one applicator insertion and their clinical relevance[J]. Radiother Oncol, 2013, 107(1): 26-31.
  • 9Petri P, Hudej R, Rogelj P, et al. Uncertainties of target volume delineation in MRI guided adaptive brachytherapy of cervix cancer: A multi-institutional study[J]. Radiother Oncol, 2013, 107( 1 ): 6-12.
  • 10王佳浩,赖建军,唐荣军,李夏东,邓清华,吴稚冰,吴式琇,马胜林.结合EPID与EUD方法确定宫颈癌病例靶区最佳生物外放边界的研究[J].中国医学物理学杂志,2013,30(5):4378-4382. 被引量:2

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部